Business Briefs

May. 16, 2013 @ 09:00 PM

Durham chamber event to focus on innovation

DURHAM – The Greater Durham Chamber of Commerce is planning a discussion on June 7 called “The Next” that will focus on discoveries and innovations that will impact the local community and world.

There will be 18-minute keynote speeches and five-minute speeches from industry experts and thought leaders.

The event will be held from 1 to 4 p.m. June 7 at The Carolina Theatre downtown.

“The Next is a high-energy event designed to make a big impact through brief presentations,” said Casey Steinbacher, the chamber’s president & CEO, in a statement. “We have some top-notch speakers lined up and look forward to attendees hearing first-hand what the next big thing is.”

The discussion is part of Paradoxos, a two-day event to be held June 6-7 to showcase the city. General admission tickets to The Next are $10. They are available via Ticketmaster or through the Paradoxos website.

 

Oxygen Biotherapeutics gets Nasdaq listing extension

MORRISVILLE – Oxygen Biotherapeutics has an extension to get into compliance with minimum Nasdaq requirements for staying listed on the exchange.

A Nasdaq listing qualifications panel granted a request for an extension through June 3 for the company to get into a compliance with a rule requiring a minimum bid price of $1. The company also said it has until July 31 to get into a compliance with a requirement for a minimum of $2.5 million in stockholders’ equity for staying listed.

The decision followed a hearing held in May.

Oxygen Biotherapeutics is working on medical products aimed at more efficiently delivering oxygen to tissues in the body to aid in healing.

Its oxygen carrier Oxycyte is in clinical and preclinical trials for intravenous treatment of traumatic brain injury, decompression sickness and stroke.

 

Quintiles, Merck Serono form partnership

DURHAM – Quintiles will be the primary provider of Merck Serono’s outsourced global clinical program clinical development services, according to a news release from the Durham-based biopharmaceutical services company.

Quintiles manages clinical trials and provides other contract services for pharmaceutical companies. The company has a new five-year agreement with Merck Serono, the biopharmaceutical division of Merck, through which it will direct the planning and execution of clinical trials for the business, according to a news release.

The goal is to speed delivery of new therapeutic options in Merck Serono’s research areas of neurology, oncology, immuno-oncology and immunology.

Quintiles is a company that recently went public, with more than 27,000 employees in about 100 countries. Quintiles offered and sold 13.125 million shares and shareholders sold another more than 14.1 million shares.

 

Bayer CropScience marked facility opening

DURHAM – Bayer CropScience recently opened 40,000 square feet of laboratory and other space at its North American headquarters in the Research Triangle Park, where the company plans to do crop protection and environmental science research.

The company said in a news release that it made a $16.1 million investment in renovations and remodeling to allow the location to be the global center for seed growth formulations as well as the U.S. center for product safety and seed growth technology.

“New and renovated facilities will give us increased capabilities to develop agricultural products for the North American and global markets,” said Adrian Percy, the company’s global head of regulatory affairs, in a statement..

Development activities in the facilities include testing and developing new chemistries for seed growth formulations and performing a range of safety studies to ensure Bayer CropScience products are safe to the environment and consumers. Laboratory space will also allow for research on formulations to protect homes, businesses and recreational areas from pests.